Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Shattuck Labs, Inc.NASDAQ: STTK

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 112.23M shares rose 120.2% year over year, ahead of the +66.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +120.2% holds above the trailing-twelve-month pace of +66.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
112.23M+8.1% QoQ
Last fiscal yearDec 2025
69.58M+37.1% YoY
LTMMar 2026
84.8M+66.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+120.2%——
1 year+37.1%——
3-year CAGR+18.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
69.58M USD
Year-over-year change
+37.1%
4-year CAGR
+13.4%

Weighted Avg Shares (Diluted) vs competitors

How STTK compares with its peers on the latest reported figures

  • STTK's LTM Mar 2026 weighted avg shares (diluted) of 84.8M shares is the 3rd highest of the 10 companies compared; the peer median is 50.86M shares.
  • Its year-over-year change of +66.7% is the 3rd highest of 10, against a peer median of +3.4%.
  • Over three fiscal years its annual growth of +18.0% compares with a peer median of +4.1%.
STTK Competitors Peer median
Weighted Avg Shares (Diluted) for STTK and competitors
Company Period LTM YoY 3-year CAGR
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +94.5%+77.8%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -11.6%-20.4%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 202657.01M +0.9%+16.7%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.86M +3.4%+4.1%
PDSBPDS Biotechnology CorporationLTM Mar 202648.66M +29.4%+17.5%
CBIOCrescent Biopharma, Inc.LTM Mar 202617.74M -57.8%-41.7%
INDPIndaptus Therapeutics, Inc.LTM Mar 20263.96M -56.9%-51.1%
FTHFaeth Therapeutics, Inc.LTM Jun 20262.37M +87.9%-6.4%
Peer median (excluding STTK) 50.86M+3.4%+4.1%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.